MDGL
Madrigal Pharmaceuticals
MDGL
Meridian score31
ResearchNot researched
QualityQuality: 75th percentile
MomentumMomentum: 45th percentile
GrowthGrowth: 39th percentile
ValuationValuation: 5th percentile
ExpectationsExpectations: 88th percentile
Evidence to review
- Financial comparability: Growth comparisons span material statement or share-base changes.
- Financial comparability: Operating profitability improved but remains weak, with a net loss.
Price and trend
Price$437.74
1M-15.3%
3M-18.8%
6M-15.8%
52w position19.9%
From high-28.8%
Relative volume0.9x
As ofOct 26, 2026
Above 21d: noAbove 50d: noAbove 200d: no50d over 200d: yes